The COVID-19 Omicron XBB.1.5 subvariant nearly doubled in prevalence over the past week, data from the U.S. Centers for Disease Control and Prevention (CDC) showed on Friday, with it now comprising over 40 percent of new cases in the United States.
Meanwhile, subvariants BQ.1 and BQ.1.1 are now at 26.9 percent and 18.3 percent of total new U.S. cases, respectively. Last week, BQ.1.1 was 33.2 percent and BQ.1 was at 24.1 percent of new cases.
The XBB.1.5 subvariant appeared in the United States around late November and has roughly doubled in prevalence every week since, according to CDC data. It accounts for the majority of current COVID-19 cases in the U.S. northeast, at around 75 percent of cases in the New York tri-state area and New England.
XBB ‘Highly Transmissible’: Japanese Researchers
XBB.1.5 descended from the XBB subvariant. The latter was first identified in India in August and quickly became dominant in the country. XBB has also been responsible for the increase in COVID-19 cases in parts of Asia, including Singapore.XBB is a recombinant of two subvariants that descended from the Omicron BA.2 subvariant. This means that genetic data from two versions of the virus that descended from BA.2 that had infected a person at the same time, combined during the viral replication process to form the new XBB subvariant.
XBB.1.5 Spreading Faster
Yunlong Richard Cao, a Chinese scientist and assistant professor at Peking University, noted that XBB.1.5 has an additional change compared to XBB called the S486P mutation, which gives it a “greatly enhanced” ability to bind to cells through a key receptor called ACE2, or angiotensin-converting enzyme 2.“We now report findings that indicate that such concerns are, sadly, justified, especially so for the XBB and XBB.1 subvariants,” they wrote. Part of their findings showed that the new subvariants—Omicron BQ.1, BQ.1.1, XBB, and XBB.1—were able to evade being neutralized by antibodies “from vaccinated individuals with or without prior infection, including persons recently boosted with the new bivalent [booster vaccine].”
“[I]t is alarming that these newly emerged subvariants could further compromise the efficacy of current COVID-19 vaccines and result in a surge of breakthrough infections as well as re-infections,” the scientists wrote. “However, it is important to emphasize that although infections may now be more likely, COVID-19 vaccines have been shown to remain effective at preventing hospitalization and severe disease even against Omicron as well as possibly reducing the risk of [long COVID].”
In the United States, vaccine manufacturers are immune from liability for any adverse reactions unless there’s “willful misconduct” involved.
The federal government has a countermeasures program that can compensate eligible persons who suffer serious injury from approved vaccines. But the burden of proof has proven a challenging process.